Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990), or Kelun-Biotech, reacquired a negotiable certificate of deposit from Tongwei (SHA:600438) for 53 million yuan, according to a Thursday filing with the Hong Kong bourse.
The large-denomination certificate of deposit had a principal amount of 50 million yuan and was first issued to Kelun-Biotech by Industrial Bank (SHA:601166) in May 2024. It was then sold to Tongwei in March by the company, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。